ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2018

Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus.

Marc Evans et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.